Δημοσίευση στις 2017/5/4 στο PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28462714
Tsioufis C, Dimitriadis K, Kordalis A, Doumas M, Konstantinidis D, Kalos T, Mahfoud F, Papademetriou V, Tousoulis D.
Although the first results from studies suggested important benefits regarding blood pressure (BP) control in resistant hypertension by the use of diverse systems of renal denervation (RDN) in the setting of resistant hypertension, the Symplicity HTN-3, randomized sham-controlled trial reduced the enthusiasm and led to a more critical approach towards this neuromodulation innovative therapy. Nowadays there is an ongoing research attempt to justify the pathophysiological background of RDN since overdrive of the sympathetic nervous system is one of the key mechanisms leading to the development and progression of the hypertensive and cardiovascular diseases.
Future RDN trials based on the clinical findings and gaps from previous works will try to identify those parameters to help identify better BP response, target the most suitable population and conclude whether this interventional approach can contribute to the clinical problem of uncontrolled hypertension.
Copyright© Bentham Science Publishers; For any queries, please email at email@example.com.